ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 808

Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells (MVECs) Is Associated with Impaired Responses to Vascular Endothelial Growth Factor (VEGF) and Defective Angiogenesis

bashar kahaleh1, Nezam Altorok2, Yongqing Wang3, Shadia Nada2, Mohammed Madkhali3 and John Sun3, 1Rheumatology, University of Toledo, Toledo, OH, 2Medicine/Rheumatology, University of Toledo, Toledo, OH, 3University of Toledo, Toledo, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Angiogenesis, endothelial cells and scleroderma, MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Impaired angiogenesis in SSc is a crucial component of disease pathology that occurs in spite of upregulation of VEGF and other proangiogenic factors. MicroRNA-126 (miR-126) is expressed mainly in MVECs throughout the capillaries. MiR-126 regulates angiogenic signaling and responses to VEGF by direct repression of negative regulators of VEGF signalling pathway, including the Sprouty-related protein-1 (Spred1), and phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2). In this study we investigated the expression levels of miR-126 and VEGF responses in SSc and control MVECs.

Methods: <span’arial’,’sans-serif’;”>MVECs were isolated from involved SSc skin and matched healthy subjects. The expression of miR-126 was measured by qPCR. The expression levels of VEGF inhibitors Spred1 and PIK3R2 were examined by qPCR and western analysis. The angiogenic potentials of MVECs were tested in a matrigel-based tube formation assay and in scratch test migration assay. <span’arial’,’sans-serif’;”>The expression of miR-126 was inhibited in control-MVECs by transfecting cells with has-miR-126 inhibitor and enhanced in SSc-MVECs by transfecting cells with has-miR-126 Mimic. 

Results:   miR-126 expression levels in SSc-MVECs and exosomes were significantly down regulated by over 10 folds in SSc-MVECs and 5 folds in SSc-exosomes (1.2 x107 miR-126 molecules/1million RNU44 molecules in control-MVECs and 8×105 in SSc-MVECs). Increased mRNA expression levels of Spred1 (2.5 folds ±0.2) and PIK3R2 (3.4±0.3 folds) in SSc-MVECs were noted by qPCR and confirmed by western analysis. Addition of VEGF (50ng/ml) to control-MVECs resulted in robust tube formation with and average branch length of (246.83±28.69 um) whereas diminished responses were seen in SSc-MVECs (88.58±15.46uM). Addition of VEGF enhanced control-MVECs migration and resulted in 50% wound closure in 6 hours, while this response was significantly diminished in SSc-MVECs (5%).  Control-MVECs transfected with miR-126 inhibitor repressed miR-126 expression levels by 78% for up to 96 hours as measured by qPCR. This was associated with significant upregulation of mRNA and protein expression levels of Spred1 and PIK3R2 and reduced angiogenic capacity to levels comparable to that of SSc-MVECs. has-miR-126 Mimic transfection to SSc-MVECs resulted in upregulation of miR-126 expression, reduced expression of Spred1 and PIK3R2, and enhanced angiogenic potentials to levels comparable to control-MVECs.  

Conclusion: <span’arial’,’sans-serif’;”>The data demonstrate impaired angiogenic potential of SSc-MVECs and diminished response to VEGF that was associated with significant down regulation of miR-126 in SSc-MVECs. Inhibition of miR-126 in control-MVECs resulted in impaired responses to VEGF, whereas forced expression of miR-126 in SSc-MVECs upregulated VEGV responses and normalized the angiogenic potential of SSc-MVECs. The data suggest that down regulation of miR-126 play a major role in impaired angiogenesis potential of SSc-MVECs.


Disclosure: B. kahaleh, None; N. Altorok, None; Y. Wang, None; S. Nada, None; M. Madkhali, None; J. Sun, None.

To cite this abstract in AMA style:

kahaleh B, Altorok N, Wang Y, Nada S, Madkhali M, Sun J. Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells (MVECs) Is Associated with Impaired Responses to Vascular Endothelial Growth Factor (VEGF) and Defective Angiogenesis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/down-regulation-of-microrna-126-in-scleroderma-microvascular-endothelial-cells-mvecs-is-associated-with-impaired-responses-to-vascular-endothelial-growth-factor-vegf-and-defective-angiogenesi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/down-regulation-of-microrna-126-in-scleroderma-microvascular-endothelial-cells-mvecs-is-associated-with-impaired-responses-to-vascular-endothelial-growth-factor-vegf-and-defective-angiogenesi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology